Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 4/20 | 0.34 |
| ▸ | TDO2 | P48775 | 4/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23962008 | 0.90 | LMNA (0.36) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL23961932 | 0.90 | LMNA (0.36) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL23962032 | 0.88 | TSHR (0.38) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL18880167 | 0.87 | LMNA (0.41) | LMNAKDM4EHTTSMN1; SMN2TSHR | |
| SCHEMBL24701748 | 0.87 | KDM4E (0.37) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL23961976 | 0.87 | LMNA (0.38) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL23847556 | 0.87 | HTR1A (0.37) | LMNAALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL14315405 | 0.87 | KDM4E (0.49) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL23961926 | 0.86 | LMNA (0.36) | LMNAKDM4EHTTSMN1; SMN2NOTUM | |
| SCHEMBL15606230 | 0.84 | HSD17B3 (0.47) | KDM4EHTTSMN1; SMN2NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | LMNA 2253/4885KDM4E 1881/4885HTT 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.